Bruton tyrosine kinase inhibitors (BTKi) (ibrutinib, acalabrutinib, and zanubrutinib) are approved as second-line therapy for MCL in the context of relapsed/refractory (R/R) disease. Here, BTK is linked to mantle cell lymphoma.